



Canadian Hemophilia Society  
Help Stop the Bleeding  
Société canadienne de l'hémophilie  
Arrêtons l'hémorragie

## **Advate® approved for use in Canada**

**August 2, 2006, MONTREAL** - Baxter announced today that its recombinant factor VIII therapy, Advate®, has been approved for use by Health Canada for the treatment of hemophilia A.

“The Canadian Hemophilia Society is pleased to see the launch of Advate,” said CHS President, Eric Stolte. “A component of quality factor replacement therapy requires that a patient and his/her physician have the option to choose products which meet a patient’s individual needs. We therefore welcome the addition of Advate to the range of quality recombinant factor VIII products currently approved by Health Canada and other international regulators, and available to Canadians with factor VIII deficiency hemophilia.”

It is expected that Canadian Blood Services and Héma-Québec, which distribute clotting factor concentrates to hemophilia treatment centres in Canada, will gradually phase out the current Baxter therapy, Recombinate®, and replace it with Advate over a period which will last several months.

For more information on Advate, see the Spring 2004 issue of Hemophilia Today (Vol 39, NO 1).